Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UMPS | P11172 | 1/20 | 0.53 |
| ▸ | NT5E | P21589 | 2/20 | 0.52 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.51 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.51 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14946368 | 1.00 | UMPS (0.53) | UMPSNT5EP2RY6P2RY2P2RY4 | |
| SCHEMBL14929324 | 1.00 | UMPS (0.53) | UMPSNT5EP2RY6P2RY2P2RY4 | |
| SCHEMBL31685569 | 0.90 | UMPS (0.66) | UMPSNT5EP2RY6P2RY2P2RY4 | |
| SCHEMBL15810653 | 0.89 | UMPS (0.62) | UMPSNT5EP2RY6P2RY2P2RY4 | |
| SCHEMBL18852571 | 0.89 | UMPS (0.62) | UMPSNT5EP2RY6P2RY2P2RY4 | |
| SCHEMBL17211014 | 0.89 | UMPS (0.62) | UMPSNT5EP2RY6P2RY2P2RY4 | |
| SCHEMBL21742443 | 0.86 | P2RY6 (0.69) | NT5EP2RY6P2RY14 | |
| SCHEMBL29185234 | 0.84 | NT5E (0.67) | NT5EP2RY6P2RY2P2RY4 | |
| SCHEMBL14946397 | 0.84 | NT5E (0.67) | NT5EP2RY6P2RY2P2RY4 | |
| SCHEMBL18574264 | 0.84 | NT5E (0.67) | NT5EP2RY6P2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210308283-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2021-10-07 | — | — | US | disclosed |
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX, INC. | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210308283-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | UMPS 36/4885NT5E 10/4885P2RY6 339/4885 |
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | UMPS 36/4885NT5E 10/4885P2RY6 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.